Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.

Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, July 21, 2026, 11:00-11:30 AM CT

Learning Objectives:
  • Explain how transparency and manufacturer partnerships improve quality, consistency, and decision-making confidence in specimen management.
  • Evaluate blood collection tubes beyond cost and commodity assumptions, incorporating clinical impact and risk into decision-making.
  • Assess the potential risk points when using a blood collection device that has not been cleared for a specific purpose.

Roundtable presenters Nick Fingland, PhD, PMP, Senior Director, R&D Operations and Science, BD, and Chris Farnsworth, PhD, D(ABCC), Section Head of Clinical Chemistry, Professor of Pathology and Immunology, Washington University School of Medicine.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, July 29, 2026, 1:00-2:00 PM ET
Learn about digital pathology technology that is future-ready, yet practical for today’s
laboratory needs.

Webinar presenters Scott Hammond, Senior Systems Consultant, Digital Pathology Division, Wexner Medical Center-Department of Pathology, and Ursula Hofer, Imaging Technologist, Pathology Digital Imaging Lab, Wexner Medical Center-Department of Pathology.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

ARTICLES

ASCO to shine light on multimodal AI models:
Plus, melanoma diagnostics and gastroesophageal cancer targets

April 2026—Artificial intelligence, circulating tumor DNA, trial data: ASCO 2026 next month in Chicago will feature platforms, technologies, and therapeutic approaches once considered future concepts in cancer diagnosis and care. What comes now is less flashy than a breakthrough advance perhaps, but no less significant. As Janice Lu, MD, PhD, puts it, “The real work now is disciplined clinical translation: validation, collaboration, and implementation, in ways that truly improve patient care.”

New susceptibility subsection with a broad scope

April 2026—A new general susceptibility subsection in the microbiology checklist consolidates requirements for antibacterials, antifungals, and antimycobacterials, aiming for clarity and a broader focus beyond bacteriology.

Speed, scale, and simplicity in microarray analyzer

April 2026—CAP TODAY publisher Bob McGonnagle spoke on Feb. 19 with Thermo Fisher Scientific’s Ravi Gupta, MBA, VP and general manager; Robert Balog, PhD, MBA, senior director, research and development; and Poulomi Acharya, PhD, senior director, global product management and market development, genetic sciences.

Ravi Gupta
Gupta
Robert Balog
Dr. Balog

Read the article:

Bob McGonnagle: Thermo Fisher launched last fall the SwiftArrayStudio, a next-generation microarray analyzer that will support genomics research and clinical applications through the use of laboratory-validated and -developed tests. Ravi Gupta, what motivated the development of this analyzer?

Ravi Gupta: The SwiftArrayStudio resulted from listening to customers. It addresses the scientific and operational pressures observed in modern genomics. I call them the real-world needs. For decades, labs across human predictive genomics and agrigenomics have dealt with persistent challenges in workflow complexity, inconsistent turnaround times, and escalating costs. Continue reading …

Watch the full conversation:

This roundtable discussion is sponsored by Thermo Fisher Scientific.

No age too early: lab exposure through children’s books

April 2026—Two new children’s books aim to introduce young readers to the world of laboratory medicine. Mia the Marvelous Lab Explorer follows a young superhero pathologist as she helps diagnose a young boy with leukemia, while ABCs of Laboratory Medicine uses the alphabet to explain various laboratory concepts.

Alzheimer’s blood tests poised to lead

March 2026—For a pathology that is invariably associated with dimming—of memory, of relationships, of personality—Alz-heimer’s disease has been linked to remarkably bright news as of late. Blood-based biomarkers, including two that garnered FDA approval last year, have cracked open the door to earlier diagnoses and therapeutic interventions, as well as the potential to reach more patients.

In MS diagnosis, the case for κ-FLC index

March 2026—An international panel of experts in multiple sclerosis and cerebrospinal fluid diagnostics reached a consensus in 2023, and they recommended including the determination of intrathecal kappa free light chain synthesis in the next revision of MS diagnostic criteria as an additional tool to measure intrathecal immunoglobulin synthesis.

Easing, clarifying of personnel requirements: ’25 accreditation checklists

March 2026—More flexibility and less burden sum up the personnel requirement changes in the accreditation program checklists released in December last year. The revisions to the CAP checklists stem from changes that the Centers for Medicare and Medicaid Services announced on June 23, 2025 in response to feedback the CMS had received about what it required in the CLIA final rule implemented on Dec. 28, 2024. The announcements were in CMS memorandum QSO-25-21-CLIA (CLIA Enforcement Discretion and Clarification on Personnel Regulations) and QSO-25-10-CLIA Revised (Revisions to State Operations Manual, Appendix C–Advance Copy).

MARKETPLACE

TRENDING